Type III TGF-[beta] receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma

Introduction Neuroblastoma (NB), the most common cancer in infancy (1), arises from developing neurons in the sympathetic ganglia or adrenal gland. While early-stage tumors are treated effectively and may regress [...]
Growth factors and their receptors coordinate neuronal differentiation during development, yet their roles in the pediatric tumor neuroblastoma remain unclear. Comparison of mRNA from benign neuroblastic tumors and neuroblastomas revealed that expression of the type III TGF-receptor (TGFBR3) decreases with advanc-ing stage of neuroblastoma and this loss correlates with a poorer prognosis. Patients with MYCN oncogene amplification and low TGFBR3 expression were more likely to have an adverse outcome. In vitro, T[beta]RIII expression was epigenetically suppressed by MYCN-mediated recruitment of histone deacetylases to regions of the TGFBR3 promoter. T[beta]RIII bound FGF2 and exogenous FGFR1, which promoted neuronal differentiation of neuroblastoma cells. T[beta]RIII and FGF2 cooperated to induce expression of the transcription factor inhibitor of DNA binding 1 via Erk MAPK. T[beta]RIII-mediated neuronal differentiation suppressed cell proliferation in vitro as well as tumor growth and metastasis in vivo. These studies characterize a coreceptor function for T[beta]RIII in FGF2-mediated neuronal differentiation, while identifying potential therapeutic targets and clinical biomarkers for neuroblastoma.